Orion Group Holdings Reports 4th Quarter and Full Year 2025 Results and Initiation of 2026 Guidance HOUSTON, March 03, 2026 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company” or “Orion”), a leading specialty construction company, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Highlights for the year ended December 31, 2025: ($ in millions, except EPS) Revenue of $852 million, GAAP net income of $2.5 million or $0.06 per diluted share, Adjusted EBITDA of $45 million and Adjusted EPS of $0.25 per diluted shareCash ...
Myriad Commercially Launches Precise MRD with Select Community Oncologists Launch Represents Significant Step to Broader Commercialization SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the ™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. “The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. By detecting ctDNA at extremely low...
Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr
Fossil Group, Inc. Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call RICHARDSON, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) announced today that it will report fourth quarter and full year 2025 financial results after market close on Wednesday, March 11, 2026, followed by a conference call to discuss the results at 5:00 p.m. ET the same day. The call can be accessed live on the Company’s investor relations website at /investors and will also be archived for replay. About Fossil Group, Inc. Fossil Group, Inc. is a gl...
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its TM (Molecular Residual Disease) Test, ® Prostate Cancer Prognostic Test and ® Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification,...
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, H...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical validation of the in Clinical Chemistry. The showed that each component of the test had exceptional sensitivity and specificity. Titled “Simultaneous prenatal cfDNA screening of aneuploidy, recessive single-gene condit...
Cabot Corporation Announces Production Capabilities in Asia Pacific for Circular Reinforcing Carbons Powered by its EVOLVE Sustainable Solutions Technology Platform Company now has capabilities across key regions to advance sustainable offerings BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- (NYSE: CBT) today announced the availability to produce in Asia Pacific its circular reinforcing carbons powered by its EVOLVE Sustainable Solutions technology platform. As such, Cabot's manufacturing facilities in Cilegon, Indonesia and Tianjin, China have successfully validated their ability to produc...
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 Management will participate in three upcoming investor healthcare conferences SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of ...
Figure 1. 4Q25 ResultsSource: Company reports, Wedbush Estimates, Visible Alpha ConsensusExpedia reported strong 4Q results with gross bookings and adj. EBITDA well ahead of estimates. Room night growth in the quarter of +8.8% Y/Y (94mm) was above St. estimates by ~130bps. Gross bookings of $27.0B
Figure 1. 4Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusAirbnb reported strong 4Q results and provided a healthy outlook for 1Q. Nights and Experiences booked growth in 4Q of +15.9% Y/Y was ~560bps above Street estimates. Revenue and adj. EBITDA were ahead of expectations
Donna Karan New York Presents The Edit, the Spring 2026 Campaign Featuring Adriana Lima, Joan Smalls and Grace Elizabeth NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Donna Karan New York continues its reemergence with The Edit: a curated fashion campaign shaped by three women whose presence transcends trend, age, and moment. Adriana Lima, Joan Smalls, and Grace Elizabeth bring their distinct points of view to the brand’s design DNA, selecting and styling a personal edit from the wider collection for an intimate dialogue between women and their wardrobes. Highlighting the talents’ pe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.